Viewing Study NCT02721459

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 2:32 PM
Ignite Modification Date: 2026-02-03 @ 11:25 AM
Study NCT ID: NCT02721459
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-12-08
First Post: 2016-03-23
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Melanoma View
None Skin Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None unresectable melanoma View
None stage III melanoma View
None stage IV melanoma View
None AJCC melanoma staging View
None American Joint Committee on Cancer (AJCC) View
None BRAF V600 E mutation View
None BRAF V600 K mutation View